Theodorus L. Ponsioen - Publications

Outcomes in Neovascular Age-Related Macular Degeneration with Visit Gaps under Anti-VEGF Therapy in Daily Practice: Data from the Fight Retinal Blindness! Registry.

Journal: Ophthalmology. Retina

Published: December 12, 2025

Suspending vascular endothelial growth factor inhibitors in eyes with retinal vein occlusion.

Journal: The British journal of ophthalmology

Published: October 04, 2025

Real-world treatment outcomes of aflibercept versus bevacizumab for neovascular age-related macular degeneration.

Journal: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie

Published: August 19, 2025

Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF.

Journal: Ophthalmology and therapy

Published: March 18, 2025

Bevacizumab in age-related macular degeneration: more injections, better vision, at lower costs

Journal: Nederlands tijdschrift voor geneeskunde

Published: February 27, 2025

Progression of Loss of Vision From Centre-Involving Macular Atrophy in Eyes Treated for nAMD.

Journal: Clinical & experimental ophthalmology

Published: January 08, 2025

Outliers of Treatment Frequency in Retinal Vein Occlusion: 24-Month Comparative Analysis of Fight Retinal Blindness! Practitioners.

Journal: Clinical & experimental ophthalmology

Published: August 25, 2024

Impact of cataract surgery on patients receiving intravitreal therapy for retinal vein occlusion.

Journal: Clinical & experimental ophthalmology

Published: August 12, 2024

Three-Year Outcomes of VEGF Inhibitors in Naive Branch Retinal Vein Occlusion: Fight Retinal Blindness!

Journal: Ophthalmology. Retina

Published: October 30, 2023

Safety, effectiveness, and cost-effectiveness of immediate versus delayed sequential bilateral cataract surgery in the Netherlands (BICAT-NL study): a multicentre, non-inferiority, randomised controlled trial.

Journal: Lancet (London, England)

Published: February 01, 2023

Central Retinal Vein Occlusion 36-Month Outcomes with Anti-VEGF: The Fight Retinal Blindness! Registry.

Journal: Ophthalmology. Retina

Published: August 23, 2022

Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry.

Journal: The British journal of ophthalmology

Published: September 19, 2021